ArticleLeukemia2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Abstract readLetter
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Ziftomenib in Relapsed or RefractoryJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- The Fanconi anemia pathway restrains MLL-rearranged leukemogenesis through suppressing non-homologous end joining-mediated genomic instability.Nature communications · 2026Article
- IKZF1Leukemia · 2026Article
- Targeting Menin in T-lineage Acute Lymphoblastic Leukemia.Molecular cancer therapeutics · 2026Article
- Review
- Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.Blood advances · 2026Article
- Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation.CPT: pharmacometrics & systems pharmacology · 2026Article
- Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia.The FEBS journal · 2026Review
- Advancements in targeted therapies for acute myeloid leukemia.Current opinion in pharmacology · 2026Review
- Ziftomenib: First Approval.Drugs · 2026Review
- Review
- The diagnostic potential of nanobodies in acute myeloid leukemia.Molecular biology reports · 2026Review
- Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy.NPJ precision oncology · 2025Review
- ZMYND11 Restrains KMT2A to Enable a Neuronal Developmental Program.bioRxiv : the preprint server for biology · 2025Article
- Chromatin Regulatory Targets for Anticancer Therapeutics.Chemical reviews · 2025Review
- Targeted and epigenetic therapies for acute myeloid leukemia treatment.Discover oncology · 2025Review
- Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia.Biomedicines · 2025Review
- Targeted protein degradation for cancer therapy.Nature reviews. Cancer · 2025Review
- Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.International journal of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Warren FiskusThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-7343-6214
Naval DaverThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-7103-373X
Steffen BoettcherUniversity of Zurich and University Hospital Zurich, CH-8091, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-9937-0957
Christopher P MillThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
Koji SasakiThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-9140-0610
Christine E BirdwellThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
John A DavisThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
Kaberi DasThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-4702-0386
Koichi TakahashiThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-8027-9659
Tapan M KadiaThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-9892-9832
Courtney D DiNardoThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-9003-0390
Francis BurrowsKura Oncology, Inc., San Diego, CA, 92130, USA.
Sanam LoghaviThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-8980-3202
Joseph D KhouryThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-2621-3584
Benjamin L EbertHoward Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0003-0197-5451
Kapil N BhallaThe University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA. kbhalla@mdanderson.org.ORCID http://orcid.org/0000-0001-5209-5126
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7MBiology and novel therapy of AML expressing somatic or germline mutant RUNX1R01CA255721 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHALLA, KAPIL, DINARDO, COURTNEY · 2021 to 2025
$2.4MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA255721
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinHumansMutationNuclear ProteinsMyeloid-Lymphoid Leukemia ProteinNuclear Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.